Genetic predictors of clonal contraction and hematologic response in IDH mutant myeloid malignancies
· 2026-09-08 · 原文
DOI：10.64898/2026.09.03.26361825v1?rss=1
IDH inhibitors promote differentiation and hematological improvement in myeloid malignancies by reversing epigenetic dysregulation. However, molecular predictors of response remain poorly defined. We retrospectively analyzed 79 patients with IDH mutated myeloid malignancies treated with either ivosidenib (IDH1; n=36) or enasidenib (IDH2; n=43). Hematologic benefit was assessed using a composite complete hematologic response (CHR), defined by neutrophil and platelet recovery, and transfusion independence. Targeted sequencing was performed at baseline and at best hematologic response. Associations between co mutations, hematologic response, and treatment duration were evaluated using multivariable models. Overall, 43% of patients achieved CHR, with similar rates between inhibitors. Ivosideni
讲义
讲义·推断 依据「原文」自动生成的结构化摘要（推断），非原文表述；以原文为准。
1. 人话版
IDH inhibitors promote differentiation and hematological improvement in myeloid malignancies by reversing epigenetic dysregulation.
However, molecular predictors of response remain poorly defined.
2. 领域脉络
来源板块：板块一 · 研究前沿。
3. 机制拆解
Hematologic benefit was assessed using a composite complete hematologic response (CHR), defined by neutrophil and platelet recovery, and transfusion independence.
Targeted sequencing was performed at baseline and at best hematologic response.
4. 证据与数字
We retrospectively analyzed 79 patients with IDH mutated myeloid malignancies treated with either ivosidenib (IDH1; n=36) or enasidenib (IDH2; n=43).
Overall, 43% of patients achieved CHR, with similar rates between inhibitors.
5. 反例与边界
摘要未声明局限与反例——这是需要警惕的信号，精读时先问边界。
6. 跨领域连接与意外收获
思考本文机制能否迁移到你正在跟进的问题。
7. 可复用方法
把本文机制与你手头项目对照，找一个两周内能验证的最小实验。
8. 术语表
精读时把不熟的术语记入此处，作为下次回忆的锚点。